Sentences with phrase «cell lymphoma relapsing»
Mantle Cell Lymphoma Relapsing as Disease of Skin, Orbit and CNS: An Extremely Rare Presentation and a Review of Literature
http://www.thejh.org/ Not exact matches
The therapy is approved by the U.S. Food and Drug Administration for relapsed or treatment - resistant Hodgkin lymphoma, and it is commonly prescribed to patients whose disease has progressed after autologous stem cell transplant, a procedure that replenishes the bone marrow with the patient's own healthy stem cells after therapy.
«Autologous stem cell transplant should be standard care for HIV - associated lymphoma: Multicenter, Phase II trial suggests autologous transplant should be standard of care for HIV patients with relapsed / treatment - resistant lymphoma.»
Conditional survival and excess mortality after high - dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.
The FDA granted accelerated approval to nivolumab (Opdivo), an anti-PD-1 checkpoint inhibitor, for patients with classical Hodgkin lymphoma (cHL) whose disease has relapsed or progressed after stem cell transplantation and the targeted antibody brentuximab vedotin (Adcetris).
The FDA granted approval to Yescarta ™ (axicabtagene ciloleucel, Kite / Gilead) for the treatment of adult patients with several types of non-Hogdkin large B cell lymphoma that is refractory or has relapsed after at least two previous systemic treatments.
A Phase 3, Randomized, Open - Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed / Refractory Diffuse Large B Cell Lymphoma (ZUMA - 7)
The FDA has approved the CAR T - cell therapy axicabtagene ciloleucel (Yescarta) for the treatment of large B - cell lymphomas in adults who have failed or relapsed after two or more prior treatments.
Brentuximab vedotin was previously approved by the FDA to treat cHL after relapse, cHL after stem cell transplant when a patient is at a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after failure of other treatment, and primary cutaneous ALCL after failure of other treatment.
«With the FDA's recent approval of this therapy, we believe this is a major advance in the treatment of patients with relapsed or refractory large B - cell lymphoma, and is likely to save or prolong lives of many patients,» says Neelapu.
It may be possible to treat patients with relapsed Hodgkin lymphoma (HL) with a new engineered T - cell approach that is less toxic and does not require pretreatment chemotherapy.
The US Food and Drug Administration (FDA) has granted Priority Review designation for tisagenlecleucel (Kymriah), formerly known as CTL019, for treatment of adult patients with relapsed or refractory diffuse large B - cell lymphoma (DLBCL) who are ineligible for, or have relapsed after, autologous stem cell transplant.
The US FDA has granted Priority Review designation for tisagenlecleucel (Kymriah) for treatment of adult patients with relapsed or refractory diffuse large B - cell lymphoma who are ineligible for, or have relapsed after, ASCT.
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real - world study in China
The targeted drug brentuximab vedotin (Adcetris ®)-- a monoclonal antibody linked to a chemotherapy drug — is approved to treat Hodgkin lymphoma in patients whose disease has failed to respond to other treatment and, as of August 2015, to prevent relapse following a stem cell transplant.
In addition, we have access to new agent trials through the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium, and we offer CAR T - cell therapy for eligible children with relapsed or refractory acute lymphoblastic leukemia (ALL).